Anti-SLC27A5/Fatp5 Antibody

Acyl-CoA synthetase involved in bile acid metabolism. Proposed to catalyze the first step in the conjugation of C24 bile acids (choloneates) to glycine and taurine before excretion into bile canaliculi by activating them to their CoA thioesters. Seems to activate secondary bile acids entering the liver from the enterohepatic circulation. In vitro, also activates 3-alpha, 7-alpha, 12-alpha-trihydroxy-5-beta-cholestanate (THCA), the C27 precursor of cholic acid deriving from the de novo synthesis from cholesterol.<br><br>Steinberg S.J., Mol. Genet. Metab. 68:32-42(1999).<br>Steinberg S.J., J. Biol. Chem. 275:15605-15608(2000).<br>Mihalik S.J., J. Biol. Chem. 277:24771-24779(2002).

Bile acyl-CoA synthetase; BACS;6.2.1.7; Bile acid-CoA ligase; BA-CoA ligase; BAL; Cholate--CoA ligase; Fatty acid transport protein 5; FATP-5; Fatty-acid-coenzyme A ligase, very long-chain 3; Solute carrier family 27 member 5; Very long-chain acyl-CoA synthetase homolog 2; VLCS-H2; VLCSH2; Very long-chain acyl-CoA synthetase-related protein; VLACS-related; VLACSR; SLC27A5; ACSB, ACSVL6, FACVL3, FATP5

Cancer, Cancer Metabolism, Cardiovascular, Fatty Acid Oxidation, Fatty Acids, Lipid and Lipoprotein Metabolism, Lipid Metabolism, Lipids/Lipoproteins, Metabolic Signaling Pathway, Metabolic Signaling Pathways, Metabolism, Metabolism of Lipids and Lipoproteins, Pathways and Processes, Redox Metabolism, Signal Transduction

Acyl-CoA synthetase involved in bile acid metabolism. Proposed to catalyze the first step in the conjugation of C24 bile acids (choloneates) to glycine and taurine before excretion into bile canaliculi by activating them to their CoA thioesters. Seems to activate secondary bile acids entering the liver from the enterohepatic circulation. In vitro, also activates 3-alpha,7- alpha,12-alpha-trihydroxy-5-beta-cholestanate (THCA), the C27 precursor of cholic acid deriving from the de novo synthesis from cholesterol. .